抗アンドロジェン作用を有する酢酸オサテロン投与
による犬前立腺肥大症の治療効果

1）麻布大学獣医学部臨床繁殖学研究室（〒229-8501　相模原市淵野辺1-17-71） 2）小島動物病院（〒956-0832　新津市秋葉2-14-68） 3）相模動物メディカルセンター（〒229-1116　相模原市清新8-1-6）

（2000年1月28日受付・2000年7月12日受理）

要　　　　　約 抗アンドロジェン作用を有する酢酸オサテロンを前立腺肥大症と診断された雄犬31例（年齢3〜15歳，体重3.4〜41.0kg）に投与して，有効性と安全性を検討した．投与量 により0.25mg/kg未満のL群（11例），0.25〜0.50mg/kgのM群（7例）および0.50mg/kg以上のH群（13例）の3群に分け，1日1回，7日間連日経口投与し，8日目に効果 判定した．その際，効果が認められない，あるいは不十分な例には引き続き３日間同用量 を追加投与し，15日目に再判定した．効果および副作用に関する判定は臨床症状，Ｘ線（一部超音波）検査，直腸検査，血液検査，血液生化学検査ならびに尿検査から行った．その結果 ，前立腺縮小効果はL群の3例を除く全例で顕著に認められ，改善が認められなかった3例についても，追加投与後の再判定で顕著にそれが認められた．しかし，実用性という点ではM群（0.25mg/kg）以上が，より早期の臨床症状の改善と前立腺の縮小効果 をもたらすことが判明した．全例について副作用，安全性に問題は認められなかった．―キーワード：抗アンドロジェン，犬前立腺肥大症，酢酸オサテロン． --------------------日獣会誌　54，21〜25（2001） Therapeutic Effects on Canine Prostatic Hypertrophy of Osaterone Acetate with Antiandrogen Action Shizuo KAWAKAMI＊†, Kazuyuki KANEKO, Yoshihiko KOJIMA and Tsuneyasu OHMORI ＊Department of Theriogenology, Azabu University, Faculty of Veterinary Medicine, 1-17-71 Fuchinobe, Sagamihara 229h8501, Japan SUMMARY   To evaluate its safety and usefulness, osaterone acetate, a new substance with antiandrogen action, was administered to 31 male dogs (ages 3 to 15 years, weights 3.4 to 41.0 kg) diagnosed as prostatic hypertrophy. Each dog was assigned to one of the following 3 groups: L grouph11 animals receiving less than 0.25 mg/kg, M grouph7 animals receiving 0.25〜0.50 mg/kg, and H grouph13 animals receiving 0.50 mg/kg or more. The substance was administered orally for 7 days, and effects were evaluated on the eighth day. For animals showing no improvement in clinical symptoms on that day, administration at the same dose levels was continued for 3 more days. In these cases, effects were reevaluated on the fifteenth day. Evaluations were based on clinical signs, radiography (in part ultrasonography), digital palpation, hematological examinations, blood chemistry, and urinalysis. In all but 3 animals in the L group, the prostate diminished markedly. These effects were intensified with the administration of additional doses. In terms of practical utility in reducing prostatic size and improving clinical signs, effects appeared earlier in animals in the M and H groups, which received 0.25 mg/kg or more. No animals showed any side effects, and no safety problems occurred. ―Key words : antiandrogen, canine prostatic hypertrophy, osaterone acetate. †Correspondence to : Shizuo KAWAKAMI (Department of Theriogenology, Azabu University, Faculty of Veterinary Medicine) 1h17h71 Fuchinobe, Sagamihara 229h8501, Japan　TEL 042-754-7111 --------------------J. Jpn. Vet. Med. Assoc.、54, 21〜25 (2001)